Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UDCA as Adjuvant to RRD Surgery
NCT06294847Phase 3Recruiting
- Sponsor
- Hôpital Foch
- Start
- Aug 2024
- Primary completion
- May 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rhegmatogenous retinal detachment (RRD) comparing Experimental arm: 'UDCA' with Control arm: 'Placebo' (2 arms). Primary endpoint: Difference in visual recovery (preoperative vs postoperative visual acuity) at 3 months. Started Aug 2024; status: recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
rhegmatogenous retinal detachment (RRD)
Beyond the preview
Go deeper on NCT06294847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06294847.